REAL-WORLD TREATMENT PATTERN AND EFFECTIVENESS OF PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: A MULTI-INSTITUTIONAL STUDY IN TAIWAN
6ER-027
ECONOMIC BENEFIT AND CLINICAL ADVANTAGES WITH THE INCLUSION OF PATIENTS IN CLINICAL TRIALS RELATED TO PARAMYLOIDOSIS
6ER-026
THE IMPORTANCE OF PHARMACY DEPARTMENT CLINICAL TRIALS UNIT INTERVENTION IN A CENTRE OF REFERENCE FOR THE TREATMENT OF PARAMYLOIDOSIS
6ER-025
ANTIMICROBIAL ACTIVITY OF SUBCRITICAL CO2 EXTRACT OBTAINED FROM UNDERGROUND FERULA ASAFOETIDA L.
6ER-024
LYELL'S SYNDROME IN CAR-T TREATED PATIENTS: A CASE STUDY
6ER-023
A MULTI-SECTOR SIMULATED EXPERIENTIAL PRACTICE EVENT FOR YEAR ONE PHARMACY STUDENTS
6ER-022
KNOWLEDGE, ATTITUDE AND PRACTICE ABOUT PHARMACEUTICALS IN THE ENVIRONMENT AMONG HOSPITAL PHARMACISTS IN SPAIN
6ER-021
OPIOID-SPARING STRATEGIES FOR DISCHARGE ANALGESIA PRESCRIBING IN NON-COMPLEX SURGERIES – A MISSED OPPORTUNITY.
6ER-020
WOULD CHATGPT PASS THE RESIDENT INTERNAL PHARMACIST EXAM?
6ER-019
TREATMENT BEYOND PROGRESSION WITH PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER
6ER-018
THE EFFECTIVENESS OF ADRENERGIC ALPHA ANTAGONISTS ON REDUCING RE-CATHETERIZATION RATES IN ADULTS WITH URINARY CATHETERS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
6ER-017
FACTORS PREDICTIVE OF CLINICAL OUTCOME IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING OSIMERTINIB TREATMENT: A REAL-WORLD EXPERIENCE
6ER-016
REAL-WORLD EFFECTIVENESS OF ALECTINIB AS FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER PATIENTS : AN EVIDENCE FROM TAIWAN
6ER-015
RETRACTED PHARMACOLOGY ARTICLES: A CROSS-SECTIONAL STUDY USING THE RETRACTION WATCH DATABASE
6ER-014
ASSESSING ADHERENCE TO ESC/ERS GUIDELINES FOR VASOREACTIVITY TESTING AND PRESCRIPTION OF CALCIUM CHANNEL BLOCKERS IN PULMONARY HYPERTENSION PATIENTS
